NLNK-20120921-8K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 21, 2012 (September 21, 2012)


NewLink Genetics Corporation
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
001-35342
42-1491350
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
 
 
 
 
2503 South Loop Drive
Ames, IA
50010
(Address of principal executive offices)
(Zip Code)
 
Registrant's telephone number, including area code: (515) 296-5555
 
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Section 8 - Other Events

Item 8.01.    Other Events.
 
On September 21, 2012, NewLink Genetics (NASDAQ:NLNK) announced that it will begin an investigator initiated, randomized, double blind placebo controlled Phase 2 study entitled “Phase II Study of sipuleucel-T (PROVENGE®) plus indoximod ( D-1MT/NLG8189) in the treatment of patients with asymptomatic or minimally symptomatic metastatic hormone refractory prostate cancer”. This study is done in collaboration with Dendreon Corporation (DNDN) and the Masonic Cancer Center, University of Minnesota.

The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.



Section 9 - Financial Statements and Exhibits
 
Item 9.01.              Financial Statements and Exhibits.
 
(d)  Exhibits.

Exhibit Number
 
Description
99.1
 
Press Release, dated September 21, 2012, entitled “NewLink announces an Investigator initiated Phase 2 Study of Sipuleucel-T plus Indoximod in the Treatment of Certain Men with Advanced Prostate Cancer”





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated:    September 21, 2012


 
NewLink Genetics Corporation
 
 
 
 
By:
/s/ Gordon H. Link, Jr.
 
  Gordon H. Link, Jr.
Its:
  Chief Financial Officer



4



INDEX TO EXHIBITS


Exhibit Number
 
Description
99.1
 
Press Release, dated September 21, 2012, entitled “NewLink announces an Investigator initiated Phase 2 Study of Sipuleucel-T plus Indoximod in the Treatment of Certain Men with Advanced Prostate Cancer”


5